Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
3.620
+0.120 (3.43%)
At close: May 12, 2025, 4:00 PM
3.620
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
54
Market Cap
204.93M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DSGN News
- 5 days ago - Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 11 days ago - Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy - GlobeNewsWire
- 21 days ago - Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 - GlobeNewsWire
- 25 days ago - Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Design Therapeutics to Participate in Leerink's Global Healthcare Conference - GlobeNewsWire
- 6 months ago - Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio - GlobeNewsWire